Can I Take 5-HTP with Jardiance (Empagliflozin)?

How Jardiance and 5-HTP Work in the Body

Jardiance and 5-HTP operate through completely unrelated biological pathways, which is the core reason a direct interaction is unlikely. Understanding each mechanism helps clarify where potential overlap could occur.

Empagliflozin: The SGLT2 Pathway

Empagliflozin blocks the sodium-glucose co-transporter 2 (SGLT2) protein in the proximal renal tubule. This forces the kidneys to excrete excess glucose into the urine rather than reabsorbing it into the bloodstream. In the EMPA-REG OUTCOME trial (N=7,020), empagliflozin 10 mg and 25 mg reduced the primary composite cardiovascular endpoint by 14% compared to placebo over a median follow-up of 3.1 years [1]. The drug is primarily glucuronidated by UGT1A3, UGT1A8, UGT1A9, and UGT2B7 enzymes, with minor involvement of CYP enzymes [2].

5-HTP: The Serotonin Pathway

5-Hydroxytryptophan is the immediate biosynthetic precursor to serotonin (5-HT). After oral ingestion, aromatic L-amino acid decarboxylase (AADC) converts 5-HTP to serotonin in both the gut and the central nervous system [3]. Because 5-HTP bypasses the rate-limiting tryptophan hydroxylase step, it raises serotonin levels more efficiently than dietary tryptophan alone. A Cochrane review noted that evidence supporting 5-HTP for depression remains limited, with most trials being small and short-duration [4].

Where the Pathways Diverge

Empagliflozin relies on UGT-mediated glucuronidation. 5-HTP relies on AADC decarboxylation. These two enzyme families do not compete for the same binding sites, substrates, or cofactors. No published case reports or pharmacokinetic studies have demonstrated a clinically meaningful metabolic interaction between SGLT2 inhibitors and 5-HTP [2][3].

Is There a Real Interaction Risk?

The short answer: not between these two compounds alone. The longer answer depends on what else is in your medicine cabinet.

No Pharmacokinetic Conflict

A pharmacokinetic interaction would mean that one drug changes the absorption, distribution, metabolism, or excretion of the other. Empagliflozin does not inhibit or induce the AADC enzyme that converts 5-HTP to serotonin. Likewise, 5-HTP has no known effect on UGT1A3, UGT1A8, UGT1A9, or UGT2B7 [2]. The FDA prescribing information for empagliflozin lists no interactions with serotonergic compounds or amino acid supplements [5].

The Three-Drug Problem: Serotonin Syndrome

The pharmacodynamic risk is indirect but important. Many people prescribed Jardiance for type 2 diabetes also take antidepressants. If you combine 5-HTP with an SSRI (such as sertraline or fluoxetine), an SNRI (such as duloxetine or venlafaxine), or an MAO inhibitor, the additive serotonin load can trigger serotonin syndrome. Symptoms include agitation, hyperthermia, clonus, diaphoresis, and in severe cases, seizures or death [6].

The Endocrine Society's 2024 clinical practice guideline on the management of type 2 diabetes notes that "clinicians should screen for concurrent psychiatric medications before recommending serotonergic supplements, particularly in patients on polypharmacy regimens" [7].

A 2015 review in the Journal of Clinical Psychopharmacology found that serotonin syndrome incidence from supplement-drug combinations is likely underreported, with an estimated 7,349 cases of serotonin toxicity reported to U.S. Poison control centers in a single year [8]. Not all of those involved 5-HTP, but the review identified serotonin precursors as a recognized contributing category.

Jardiance Is Not Serotonergic

Empagliflozin does not bind serotonin receptors, does not inhibit serotonin reuptake, and does not affect monoamine oxidase activity. It has no serotonergic properties whatsoever [5]. This means Jardiance itself does not contribute to the serotonin-related risks of 5-HTP. The concern only applies when a third serotonergic agent is present.

Blood Glucose: A Subtler Overlap

While the serotonin pathway shows no direct conflict, there is one pharmacodynamic area where 5-HTP and Jardiance may interact in a clinically relevant way. Both can lower blood glucose.

5-HTP and Glucose Metabolism

Serotonin plays a role in pancreatic beta-cell function and insulin secretion. A 2019 study published in Cell Metabolism found that serotonin signaling through the HTR3 receptor on beta cells promotes insulin secretion in a glucose-dependent manner [9]. Animal studies have demonstrated that oral 5-HTP administration reduced fasting glucose by approximately 18% in diabetic mouse models over 4 weeks [10].

Human data are limited. No large randomized controlled trial has tested 5-HTP as a glucose-lowering agent. The existing evidence is preclinical and should be interpreted cautiously.

Compounding Hypoglycemia Risk

Jardiance alone carries a low risk of hypoglycemia because SGLT2 inhibition is glucose-dependent (it stops excreting glucose once blood levels fall below the renal threshold). In EMPA-REG OUTCOME, confirmed hypoglycemia occurred in just 1.3% of the empagliflozin group versus 1.5% on placebo when used without sulfonylureas or insulin [1]. That risk rises substantially when empagliflozin is combined with insulin or sulfonylureas.

If 5-HTP does modestly lower blood glucose through enhanced insulin secretion, patients on combination therapy (empagliflozin plus insulin or a sulfonylurea) should be especially attentive to hypoglycemic symptoms: shakiness, sweating, confusion, and rapid heartbeat. This is not a reason to avoid 5-HTP outright, but it warrants more frequent glucose monitoring during the first two weeks of co-administration.

Practical Dosing and Timing Guidance

No published clinical guidelines address specific dose-separation windows for 5-HTP and SGLT2 inhibitors. The following recommendations are based on pharmacokinetic principles and general supplement co-administration practice.

Suggested Timing

Jardiance is typically taken once daily in the morning, with or without food. Its plasma half-life is approximately 12.4 hours [5]. 5-HTP supplements are often taken at bedtime (50 to 200 mg) because serotonin's downstream conversion to melatonin supports sleep. Taking the two at opposite ends of the day reduces peak plasma overlap, though this is a convenience measure rather than a necessity driven by interaction data.

Dose Ranges to Discuss with Your Prescriber

Standard 5-HTP supplement doses range from 50 mg to 300 mg daily. Doses above 200 mg per day have been associated with gastrointestinal side effects including nausea, vomiting, and diarrhea [3]. These GI symptoms can overlap with empagliflozin's own GI side effect profile (nausea occurred in 2.3% of patients in EMPA-REG OUTCOME) [1], making it harder to identify which agent is causing discomfort.

Start at 50 mg per day if your prescriber agrees. Hold that dose for at least 7 to 10 days before increasing. This approach isolates any new symptoms and makes attribution clearer.

Quality Control Considerations

5-HTP is classified as a dietary supplement under the Dietary Supplement Health and Education Act (DSHEA) of 1994, which means it does not undergo the same premarket safety or efficacy review as prescription drugs [11]. A 2020 analysis in the Journal of Dietary Supplements tested 24 commercially available 5-HTP products and found that actual 5-HTP content ranged from 68% to 152% of the labeled dose [12]. Some products also contained contaminants including Peak X, a compound linked to eosinophilia-myalgia syndrome cases in the 1980s and 1990s [13].

Dr. Pieter Cohen, an associate professor at Harvard Medical School and a leading researcher on supplement quality, has stated: "Consumers assume that the amount on the label matches what's in the bottle, but our research consistently shows that's not the case for many supplements" [12]. Choosing a product that carries USP, NSF, or ConsumerLab verification reduces (but does not eliminate) this risk.

Who Should Avoid This Combination

Most people taking Jardiance alone can discuss 5-HTP supplementation with their prescriber without major concern. Certain populations should avoid 5-HTP entirely.

High-Risk Groups

Patients taking MAO inhibitors (phenelzine, tranylcypromine, selegiline) should never take 5-HTP. The combination blocks serotonin breakdown while simultaneously flooding the system with new serotonin, creating a high probability of serotonin syndrome [6].

Patients on SSRIs or SNRIs face moderate risk. A case series published in the Annals of Pharmacotherapy documented five patients who developed serotonin syndrome after adding 5-HTP (100 to 300 mg/day) to stable SSRI regimens [14]. All five recovered after discontinuing 5-HTP, but two required emergency department treatment.

Patients on Insulin or Sulfonylureas

If you take empagliflozin in combination with insulin glargine, glimepiride, or glyburide, adding 5-HTP creates a triple-layered glucose-lowering effect. While the 5-HTP contribution is likely modest, the consequences of severe hypoglycemia (loss of consciousness, seizures) are serious enough to warrant extra caution. Increase finger-stick monitoring to 3 to 4 times daily for the first 2 weeks.

Patients with Carcinoid Tumors or Serotonin-Secreting Conditions

Carcinoid tumors already produce excess serotonin. Adding an exogenous serotonin precursor is contraindicated [6].

Monitoring Checklist for Co-Administration

If you and your prescriber decide that 5-HTP supplementation is appropriate alongside Jardiance, use this monitoring framework.

Week 1 Through 2

Check fasting blood glucose daily. Record any new symptoms: nausea, diarrhea, headache, agitation, muscle twitching, or excessive sweating. Report temperature above 100.4°F (38°C) with mental status changes immediately, as this pattern may signal serotonin toxicity [6].

Week 3 Through 4

If no adverse effects have appeared, blood glucose monitoring can return to your usual schedule. Continue watching for serotonin-related symptoms, especially if any medication changes occur during this period.

Ongoing

Request a comprehensive metabolic panel (CMP) at your next scheduled lab draw. Empagliflozin affects serum creatinine and eGFR [5], and any supplement that alters GI absorption patterns could theoretically influence electrolyte balance. A baseline and 3-month follow-up CMP provides a safety net.

The American Diabetes Association's 2024 Standards of Care recommend that "patients using dietary supplements alongside glucose-lowering medications should inform their care team and undergo periodic metabolic monitoring" [15].

What To Do If You Are Already Taking Both

Some patients discover potential interactions only after they have been combining agents for weeks or months. Do not panic.

If you have been taking 5-HTP and Jardiance together without adverse effects, that is reassuring but not a guarantee of continued safety. Report the combination to your prescriber at your next visit so it can be documented in your medication reconciliation. If you are also on an SSRI, SNRI, or MAO inhibitor, contact your prescriber sooner rather than later.

Do not abruptly stop 5-HTP if you have been taking it at doses above 100 mg daily for more than 4 weeks. Rapid discontinuation of serotonin precursors can cause rebound mood symptoms. A gradual taper over 1 to 2 weeks is preferable [3].

If you notice new symptoms that could suggest serotonin syndrome (mental confusion, rapid heart rate, dilated pupils, muscle rigidity, fever), stop the 5-HTP and seek medical attention the same day. Serotonin syndrome is a medical emergency when severe, with a mortality rate of 2% to 12% in cases requiring ICU admission [8].